Patients with aborted sudden death, hemodynamically unstable ventricular arrhythmias, and unexplained cardiogenic syncope are at high risk for fatal ventricular arrhythmias. If these patients have a reasonable life expectancy and stable, non-refractory heart failure, an implantable defibrillator is the approach of choice (in conjunction with beta blockade). The constraining factor is the high cost involved.